Promising Medical Stocks To Watch Now - May 16th

UnitedHealth Group, Hims & Hers Health, and Eli Lilly and Company are the three Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares of publicly traded companies operating in the healthcare sector—ranging from pharmaceuticals and biotechnology to medical devices, diagnostics, and health-care services. By buying these equities, investors gain exposure to firms developing new treatments, technologies, or care models. While they can offer growth potential tied to scientific and demographic trends, they also carry risks related to regulatory approvals, clinical trial outcomes, and changes in health-care policy. These companies had the highest dollar trading volume of any Medical stocks within the last several days.

UnitedHealth Group (UNH)

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.

Shares of NYSE:UNH traded up $15.00 during midday trading on Friday, hitting $289.35. 38,185,936 shares of the stock were exchanged, compared to its average volume of 5,743,245. The business's 50-day moving average price is $474.72 and its 200 day moving average price is $515.82. UnitedHealth Group has a 12 month low of $248.88 and a 12 month high of $630.73. The stock has a market capitalization of $262.48 billion, a price-to-earnings ratio of 18.76, a P/E/G ratio of 1.37 and a beta of 0.56. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.91 and a current ratio of 0.83.

Read Our Latest Research Report on UNH

Hims & Hers Health (HIMS)

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

HIMS traded up $2.69 during trading on Friday, hitting $61.27. The company's stock had a trading volume of 34,063,141 shares, compared to its average volume of 19,211,330. Hims & Hers Health has a twelve month low of $13.47 and a twelve month high of $72.98. The stock's fifty day moving average price is $34.85 and its 200-day moving average price is $33.40. The firm has a market capitalization of $13.71 billion, a P/E ratio of 138.96 and a beta of 1.84.

Read Our Latest Research Report on HIMS

Eli Lilly and Company (LLY)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Shares of NYSE:LLY traded up $21.96 during trading on Friday, reaching $753.75. 2,526,658 shares of the stock were exchanged, compared to its average volume of 3,578,264. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53. The stock has a fifty day moving average of $799.17 and a two-hundred day moving average of $807.15. The firm has a market cap of $714.35 billion, a price-to-earnings ratio of 64.36, a price-to-earnings-growth ratio of 1.40 and a beta of 0.48.

Read Our Latest Research Report on LLY

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.